| Literature DB >> 35692560 |
Ma de Lourdes Zuñiga Martinez1,2, Carlos Miguel López Mendoza2, Jared Tenorio Salazar2, Alejandro Manuel García Carrancá3, Marco Antonio Cerbón Cervantes4, Luz Eugenia Alcántara-Quintana5.
Abstract
Cell lines have been considered excellent research models in many areas of biomedicine and, specifically, in the study of carcinogenesis. However, they cease to be effective models if their behavior changes. Although studies on the cross-contamination of cell lines originating from different tissues have been performed, little is known about cell lines derived from cervical neoplasia. We know that high-risk HPV (HR-HPV) is associated with the development of this type of cancer. This link between HPV infection and cancer was first established over 35 years ago when HPV16 DNA was found to be present in a large proportion of cervical cancer biopsies. The present review paper aims to report the status of the establishment, authenticity, and characterization of cervical cancer (CC) cell lines. This is a systematic review of articles on the establishment, authenticity, and characterization of CC cell lines, published from 1960 to date in the databases and in cell repository databases. 52 cell lines were identified in the literature. Only 25 cell lines were derived from cervical neoplasia, of which only 45.8% have a reported identity test (genomic fingerprint). Despite the increase in the establishment of cell lines of cervical neoplasia and the standards for the regulation of these study models, the criteria for their characterization continue to be diverse.Entities:
Keywords: Cell lines; HPV (human papilloma virus); In vitro models; authenticity; cervical cancer; characterization; establishment
Year: 2022 PMID: 35692560 PMCID: PMC9176225 DOI: 10.1080/23723556.2022.2078628
Source DB: PubMed Journal: Mol Cell Oncol ISSN: 2372-3556
Figure 1.General outline of the study.
Cervical cell lines established between 1960–2020
| Criteria | No. cell line identified | Percentage |
|---|---|---|
| Not reported karyotype | 13 | 25.0 |
| Not reported genotyping HPV | 3 | 5.8 |
| Ciudad de México | 7 | 13.5 |
| Not reported general date or karyotype/genotyping | 4 | 7.7 |
| Karyotyping + Genotyping HPV | 25 | 48.0 |
| Total | 52 | 100 |
Cervical cancer cell lines characterized by karyotype and genotyping HPV
| No. | Cell line | Histology diagnosis | Race | Age | HPV | Karyotype | Reference |
|---|---|---|---|---|---|---|---|
| 1 | C4 | Exophytic invasive squamous carcinoma of the cervix stage II, grade IV | C | 41 | HPV18 | Hyperdiploid (45) | Auersperg[ |
| 2 | C33 | Invasive cervical carcinoma grade IV | C | 66 | Negative for HPV | Hyperdiploid (45) | Auersperg,[ |
| 3 | SiHa | Squamous cell carcinoma stage II | A | 55 | HPV16 | Hypertriploid (69) | Friedl[ |
| 4 | SW756 | Poorly differentiated invasive squamous carcinoma of the uterine cervix | C | 46 | HPV18 | Triploid (76) | Freedman;[ |
| 5 | SKGIII | Uterine cervical cancer stage II | A | 38 | HPV16 | Aneuploidy (42) | Nozawa;[ |
| 6 | HX151c | Poorly differentiated squamous cell carcinoma stage IB | C | 30 | HPV16 | Aneuploidy (71) | Kelland;[ |
| 7 | HX155c | Moderately differentiated squamous cell carcinoma stage IB | C | 44 | HPV16 | Aneuploidy (74) | Kelland;[ |
| 8 | HX156c | Poorly differentiated squamous cell carcinoma stage IIB | C | 31 | HPV16 | Aneuploidy (74) | Kelland;[ |
| 9 | HX160c | Moderately well-differentiated squamous cell carcinoma stage IB | C | 44 | HPV16 | Aneuploidy (73) | Kelland;[ |
| 10 | XH1 | Invasive focally keratinizing adenosquamous | C | 32 | HPV16 | Aneuploidy (78) | Han[ |
| 11 | CaLo | Epidermoid cervical carcinoma of keratinized large cell from nonmetastatic tumor stage IIB | L | 55 | HPV18 | Aneuploidy (50) | Monroy[ |
| 12 | INBL | Epidermoid cervical carcinoma of keratinized large cell from metastatic tumor stage IVB | L | NR | HPV18 | Aneuploidy (50) | Monroy[ |
| 13 | CUMC-3 | Invasive nonkeratinizing squamous cell carcinoma stage IIB | A | 32 | HPV16 | Hypotetraploid (78) | Kim[ |
| 14 | CUMC-6 | Squamous cell carcinoma of the cervix uteri | A | 31 | HPV16-18 | Diploid/trisomy (47) | Kim[ |
| 15 | TC-140 | Moderately differentiated squamous cell carcinoma with metastases to lymph nodes | C | 39 | HPV16 | Triploid (61) | Braun;[ |
| 16 | TC-146 | Moderately differentiated epidermoid carcinoma | C | 36 | HPV16 | Triploid (48) | Mark[ |
| 17 | SiSo | Adenocarcinoma of the uterine cervix stage IB | A | 67 | HPV18 | Aneuploid (61) | Sonoda[ |
| 18 | CX | Squamous cell carcinoma of the uterine cervix stage IIA | A | 48 | Negative for HPV | Euploidy | Chou[ |
| 19 | CA | Non-keratinizing squamous cell carcinoma stage IB2 | A | 36 | Negative for HPV | Aneuploid (65) | Isaka[ |
| 20 | HHUS | Uterine cervical keratinizing squamous cell carcinoma | A | 64 | HPV59 | Diploid (48) | Ishiwata[ |
| 21 | RSBS-9 | Moderately differentiated keratinizing squamous cell carcinoma stage III | A | 49 | HPV16 | Aneuploid (53) | Javed[ |
| 22 | RSBS-14 | Moderately differentiated non-keratinizing squamous cell carcinoma stage III | A | 34 | HPV16 | Aneuploid (47) | Javed[ |
| 23 | RSBS-23 | Poorly differentiated non-keratinizing squamous cell carcinoma stage III | A | 45 | HPV16 | Aneuploid (56) | Javed[ |
| 24 | RSBS-43 | Moderately differentiated adenocarcinoma of uterine cervix stage III | A | 63 | HPV16 | Aneuploid (51) | Javed[ |
| 25 | HUUCLEC | Human uterine cervical lymphoepithelial carcinoma | A | 61 | HPV56 | Aneuploid (56) | Kiguchi[ |
C= Caucasian, A= Asian, L= Latin American, NR= Not reported data.
Methods to evaluate the authenticity and characterization of cervical cell lines
| No. | Cell line | TD | No. Passages | Contact inhibition | Saturation density | Tumorigenicity | Uniqueness | Isoenzyme analysis | Contamination | Confirmation the tissue of origin |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C4 | 24-48h | 90 | No | NR | Collagen gel, hamster model | SRT, transcriptome | G6PD-B | Free of HeLa | Cytology, histochemistry, |
| 2 | C33 | 24-76h | 70 | No | NR | Murine model | SRT, transcriptome | G6PD-B, PGM1–1, AK-1 | Free of HeLa | NR |
| 3 | SiHa | 2.6 days | NR | NR | NR | Murine model | SRT, transcriptome | G6PD-B, PGM1–1, AK-1 | Free of mycoplasma, or HeLa | Desmosomes, tonofilaments |
| 4 | SW756 | 1.6 days | 100 | NR | NR | Murine model | SRT, transcriptome | G6PD-B, GLO-1,2 | Free of mycoplasma, HeLa, ME180, or C4 I | HLA typing (A1, 24, B8, 44: Cw2, x; D2 W2, 6Y) |
| 5 | SKG-III | 60-67h | 80 | No | 4x105 cell/cm2 | Murine model | SRT, transcriptome | G6PD-B | Free of HeLa | Desmosomes, tonofilaments, HLA-A 2402 |
| 6 | HX151c | 42h | 70 | NR | Low | Murine model | NR | G6PDB. PGM1–1, PGM3-a, ACP1-BA, PGD-A | Free of mycoplasma, or HeLa | Vimentin, cytokeratin |
| 7 | HX155c | 48h | 50 | NR | Low | Murine model | NR | G6PDB. PGM1–1, PGM3-a, ACP1-B, PGD-A | Free of mycoplasma, or HeLa | Vimentin, cytokeratin |
| 8 | HX156c | 30h | 75 | NR | High | Murine model | NR | G6PDB. PGM1–1, PGM3-b, ACP1-BA, PGD-A | Free of mycoplasma, or HeLa | Cytokeratin |
| 9 | HX160c | 68h | 50 | NR | Low | Murine model | NR | G6PDB. PGM1–1, PGM3-b, ACP1-B, PGD-A | Free of mycoplasma, or HeLa | Vimentin, cytokeratin |
| 10 | XH1 | 16.2h | 100 | NR | NR | Murine model | SRT | MS1 | Free of mycoplasma, HeLa, A431, CaSki, and Bowes melanoma | Antibodies to membrane antigen, carcinoembryonic antigen, desmin, vimentin and cytokeratin |
| 11 | CaLo | 3–4 days | 50 | No | High (>15,000 cell/ml) | NR | NR | NR | NR | Desmogeín-1 |
| 12 | INBL | 3–4 days | 50 | No | High (>15,000 cell/ml) | NR | NR | NR | NR | Desmogeín-1, HLA-A11 |
| 13 | CUMC-3 | 48h | 310 | No | NR | Murine model | NR | G6PD-B, LDH-4, PGM | Free of HeLa | Desmosomes, tonofilaments, HLA-DRB1 0401 |
| 14 | CUMC-6 | 36h | 300 | No | NR | Murine model with lung metastases | NR | G6PD-B, LDH, PGM | Free of HeLa | Desmosomes, tonofilaments, HLA-DQw3 |
| 15 | TC-140 | NR | NR | No | 1x105 cell/cm2 | Murine model | NR | NR | Free of mycoplasma | Histology |
| 16 | TC-146 | NR | NR | No | 1x105 cell/cm2 | Murine model | FISH | NR | Free of mycoplasma | Histology |
| 17 | SiSo | 24-35h | 34 | No | 4x105 cell/cm2 | Murine model | STR, transcriptome | NR | NR | Mucin, cytokeratin, epithelial membrane antigen |
| 18 | CX | 20h | NR | NR | NR | Not tumorigenic | RPPA, SNP, transcriptome | NR | Free of mycoplasma | Cytokeratin, desmosomes |
| 19 | CA | 14.3h | 280 | No | NR | Murine model | SRT | NR | NR | Carcinoembryonic antigen, antígeno polipéptido de tejido |
| 20 | HHUS | 67h | 70 | No | 3.9x104 cell/cm2 | Murine model | NR | NR | NR | Desmosomes, tonofilaments, carcinoembryonic antigen, cytokeratin |
| 21 | RSBS-9 | 48h | NR | Yes | NR | Tumorosphere | VNTR | NR | Free of mycoplasma | Epithelial membrane antigen, cytokeratin |
| 22 | RSBS-14 | 48h | NR | Yes | NR | Tumorosphere | VNTR | NR | Free of mycoplasma | Epithelial membrane antigen, cytokeratin |
| 23 | RSBS-23 | 48h | NR | Yes | NR | Tumorosphere | VNTR | NR | Free of mycoplasma | Epithelial membrane antigen, cytokeratin |
| 24 | RSBS-43 | 48h | NR | Yes | NR | Tumorosphere | VNTR | NR | Free of mycoplasma | Epithelial membrane antigen, cytokeratin |
| 25 | HUUCLEC | 70h | 60 | No | NR | Not tumorigenic | NR | NR | Free of virus Epstein y Barr | Cytokeratin, epithelial membrane antigen, carcinoembryonic antigen |
TD: Doubling time, NR= Not reported data, STR: Short Tandem Repeats, SNP: single-nucleotide polymorphisms, VNTR: variable number of tandem repeats, MS31: Hypervariable minisatellite probing, FISH: fluorescence in situ hybridization, RPPA: reverse phase protein arrays, ACP-1: human red cell acid phosphatase, AK-1: adenylate kinase polymorphism, G6PD: glucose 6 phosphate dehydrogenase, PGM: phosphoglucomutase, HLA: human leukocyte antigen